Bruker (NASDAQ:BRKR) Price Target Raised to $85.00

Bruker (NASDAQ:BRKR) had its price target boosted by Leerink Partners from $80.00 to $85.00 in a research report released on Thursday,Benzinga reports. Leerink Partners currently has an outperform rating on the medical research company’s stock.

BRKR has been the topic of a number of other research reports. JPMorgan Chase & Co. downgraded Bruker from an “overweight” rating to a “neutral” rating and set a $60.00 price objective on the stock. in a research report on Wednesday, October 14th. Citigroup reduced their target price on Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research report on Wednesday, August 5th. TD Cowen boosted their target price on Bruker from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 13th. Guggenheim upped their target price on Bruker from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Finally, Barclays raised their price target on Bruker from $58.00 to $70.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Bruker currently has an average rating of “Moderate Buy” and an average target price of $60.57.

Bruker Price Performance

Shares of NASDAQ:BRKR opened at $61.31 on Thursday. The company has a 50 day moving average of $59.01 and a 200 day moving average of $50.59. The stock has a market cap of $9.34 billion, a P/E ratio of -55.74, a P/E/G ratio of 1.79 and a beta of 1.26. Bruker has a 12 month low of $32.37 and a 12 month high of $68.98. The company has a current ratio of 1.84, a quick ratio of 0.92 and a debt-to-equity ratio of 0.74.

Bruker (NASDAQ:BRKR) last posted its earnings results on Wednesday, November 4th. The medical research company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.14. Bruker had a negative net margin of 3.82% and a positive return on equity of 13.76%. The business had revenue of $874.00 million for the quarter, compared to analyst estimates of $865.16 million. During the same quarter in the prior year, the firm posted $0.45 EPS. Bruker’s revenue was up 1.6% on a year-over-year basis. As a group, sell-side analysts forecast that Bruker will post 2.13 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Bruker’s dividend payout ratio is presently -18.18%.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total transaction of $105,740.00. Following the sale, the vice president owned 134,806 shares in the company, valued at approximately $7,127,193.22. This trade represents a 1.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 27.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its stake in shares of Bruker by 140.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 29,990 shares of the medical research company’s stock valued at $1,942,000 after acquiring an additional 17,534 shares during the last quarter. Maryland State Retirement & Pension System boosted its holdings in Bruker by 23.2% during the 3rd quarter. Maryland State Retirement & Pension System now owns 6,287 shares of the medical research company’s stock valued at $407,000 after acquiring an additional 1,185 shares during the period. AlphaCore Capital LLC purchased a new stake in Bruker during the 3rd quarter valued at about $410,000. Allspring Global Investments Holdings LLC boosted its holdings in Bruker by 5.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 169,766 shares of the medical research company’s stock valued at $10,515,000 after acquiring an additional 8,938 shares during the period. Finally, Brighton Jones LLC grew its position in Bruker by 11.2% during the 3rd quarter. Brighton Jones LLC now owns 12,436 shares of the medical research company’s stock worth $805,000 after acquiring an additional 1,248 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.